Product Description: Puromycin dihydrochloride (CL13900 dihydrochloride), an aminonucleoside antibiotic, inhibits protein synthesis[1].
Applications: COVID-19-immunoregulation
Formula: C22H31Cl2N7O5
Citations: Acta Pharmacol Sin. 2023 Feb 20./Adv Mater. 2022 Oct 20;e2206793./Adv Sci (Weinh). 2024 Feb 21:e2308531./Adv Sci (Weinh). 2024 Jun 26:e2404822./Aging. 2020 Sep 14;12(17):17122-17136./Aging. 2021 Jun 8;13(11):14892-14909./Am J Cancer Res. 2023 May 15;13(5):1718-1743./Am J Cancer Res. 2023 Sep 15;13(9):4222-4234./Am J Transl Res. 2021 Apr 15;13(4):2331-2349./Am J Transl Res. 2021 May 15;13(5):4360-4375./Anal Biochem. 2021 Aug 29;114357./Antioxid Redox Signal. 2022 Jun 16./Antioxidants (Basel). 2023 Aug 18;12(8):1634./Arch Biochem Biophys. 2023 May 19;109642./Autophagy. 2021 Mar 25;1-19./Bioact Mater. 12 November 2021./Biochem Biophys Res Commun. 1 January 2022, Pages 34-41./Biochem Biophys Res Commun. 2021 Oct 5;580:48-55./Biochem Biophys Res Commun. 6 August 2022./Biochem Pharmacol. 2020 Apr;174:113776./Biochem Pharmacol. 2024 Jul 10:116418./Biochem Pharmacol. 2024 Jul 10:116422./Biochem Pharmacol. 2024 May 9:225:116256./Biochim Biophys Acta Mol Basis Dis. 2024 Apr 20;1870(5):167195./Biochim Biophys Acta Mol Cell Res. 2024 Jun 3:119768./Biodes Manuf. 03 March 2022./Biol Res. 2024 May 17;57(1):30./Biomed Pharmacother. 2020 Jan;121:109578./bioRxiv. 2023 Mar 31./bioRxiv. 2023 Oct 4./bioRxiv. 2024 Mar 29./bioRxiv. April 11, 2022./BMC Cancer. 2018 Feb 13;18(1):182. /Bull Cancer. 2023 Feb 28;S0007-4551(23)00083-8./Cancer Commun (Lond). 2022 Nov 9./Cancer Immunol Res. 2023 Feb 22;CIR-22-0658./Cancer Invest. 2021 Mar 8;1-34./Cancer Lett. 2020 Nov 1;492:162-173./Cancer Lett. 2021 Apr 29;S0304-3835(21)00180-4./Cancer Lett. 2021 Jul 30;518:266-277./Cancer Lett. 2024 Apr 9:591:216848./Cancer Lett. 2024 Jan 25:216674./Cancer Manag Res. 2021 Nov 30;13:8915-8928./Cancer Med. 2019 Oct;8(13):5903-5915./Cancer Res. 2023 Apr 16;CAN-22-3059./Cancer Sci. 2024 Jun 26./Cell Commun Signal. 2022 Jun 15;20(1):87./Cell Death Dis. 2020 Dec 2;11(12):1032./Cell Death Dis. 2021 Oct 14;12(10):944./Cell Death Dis. 2021 Sep 9;12(9):842./Cell Death Dis. 2022 Apr 18;13(4):360./Cell Death Dis. 2023 Feb 11;14(2):107./Cell Death Dis. 2023 Nov 25;14(11):765./Cell Death Dis. 2023 Oct 6;14(10):653./Cell Death Dis. 2019 Nov 21;10(12):879. /Cell Death Discov. 2021 Aug 30;7(1):226./Cell Death Discov. 2021 May 1;7(1):89./Cell Death Discov. 2022 Apr 23;8(1):222./Cell Death Discov. 2022 Dec 16;8(1):493./Cell Death Discov. 2022 Feb 22;8(1):77./Cell Death Discov. 2022 Oct 28;8(1):432./Cell Mol Biol (Noisy-le-grand). 2024 Jun 5;70(6):122-128./Cell Mol Immunol. 2024 Jun;21(6):546-560./Cell Rep. 2024 Feb 27;43(2):113739./Cell Rep. 2024 Mar 23;43(4):114003./Cell Signal. 2020, 109878./Clin Epigenetics. 2022 Dec 2;14(1):164./Clin Transl Oncol. 2021 Apr 7./Clin Transl Oncol. 2022 Dec 13./Commun Biol. 2022 Aug 30;5(1):887./Comput Biol Med. 2024 Feb, 169, 107975./Dig Liver Dis. 2022 Dec 29;S1590-8658(22)00827-1./Dis Markers. 2022 Sep 23;2022:8402116./DNA Cell Biol. 2022 Apr;41(4):447-455./EMBO Rep. 2021 Jun 23;e52205./Environ Toxicol. 2023 Mar 15./Environ Toxicol. 2023 Oct 4./Exp Cell Res. 2023 Apr 11;427(1):113598./Exp Cell Res. 2023 Apr 24;113613./Exp Cell Res. 2024 Apr 16;438(1):114038./Exp Mol Med. 2022 Jul;54(7):890-905./Exp Mol Pathol. 2021 Oct 5;104704./F1000Research. 03 Aug 2022./Front Oncol. 21 April 2021./Genes (Basel). 2022, 13(10), 1760./Heliyon. 2022 Dec 6;8(12):e12118./Heliyon. 2023 Aug 9./Heliyon. 2023 Nov 15./Int Immunopharmacol. 2023 Jul 15;122:110616./Int J Biol Macromol. 2023 Apr 17;124476./Int J Mol Sci. 2023 Sep 23, 24(19), 14476./Int J Oncol. 2023 Apr;62(4):45./Int J Oncol. 2024 Apr;64(4):45./J Appl Toxicol. 2023 Apr 14./J Biol Chem. 2021 Feb 10;296:100413./J Biol Chem. 2021 Jan 8;100276./J Biol Chem. 2023 Jan 28./J Cancer. 2023 May 8; 14(8): 1309-1320./J Cell Mol Med. 2023 Mar 14./J Ethnopharmacol. 2023 Apr 3;116446./J Exp Clin Cancer Res. 2021 Nov 25;40(1):373./J Exp Clin Cancer Res. 2022 Mar 28;41(1):111./J Exp Clin Cancer Res. 2023 Nov 6;42(1):294./J Exp Clin Cancer Res. 2023 Oct 3;42(1):258./J Hematol Oncol. 2021 Jul 10;14(1):109./J Transl Med. 2024 Jun 20;22(1):584./J Transl Med. 2024 May 21;22(1):485./J Virol. 2024 Jun 28:e0083024./Life Sci. 2022 Jan 19;293:120320./Mbio. 2023 Oct 26:e0168823./MedComm (2020). 2024 May 31;5(6):e576./Mol Cancer. 2024 May 6;23(1):90./Mol Cancer. 2019 Aug 22;18(1):127. /Mol Carcinog. 2023 Jun 28./Mol Cell Biochem. 2021 Jun;476(6):2503-2512./Mol Cell. 2023 Nov 20:S1097-2765(23)00914-0./Mol Cell. 2023 Nov 24:S1097-2765(23)00911-5./Mol Pharm. 2024 Jun 6./Molecules. 2023, 28(3), 1103./Nat Commun. 2019 Dec 2;10(1):5492. /Nat Commun. 2022 Mar 10;13(1):1248./Neuro Oncol. 2022 Jun 20;noac156./NPJ Precis Oncol. 2024 Mar 1;8(1):58./Nucleic Acids Res. 2024 Jan 2:gkad1243./Oncogene. 2021 Nov 29./Oncogene. 2023 Aug 18./Oncol Lett. 2023 Dec 18./Oncol Rep. 2021 Feb;45(2):523-534./Oncol Rep. 2023 Aug;50(2):148./Oncotargets Ther. 2020 Sep 30;13:9701-9719./Peer J Prints. June 6, 2022./Phytomedicine. 2023 Mar 15;114:154769./Poult Sci. 2023 Jul 14, 102864./Reprod Biomed Online. 2023 Jun 23./Research Square Preprint. 2021 Aug./Research Square Preprint. 2021 Nov./Research Square Preprint. 2022 Jan./Research Square Preprint. 2022 May./Research Square Preprint. 2023 Apr 17./Research Square Preprint. 2023 Nov 25./Research Square Preprint. 2023 Sep 27./Research Square Print. 2022 Aug./Research Square Print. 2023 Mar 15./Sci Rep. 2022 Nov 5;12(1):18809./Science. 2024 Feb 2;383(6682):eadh4859./Signal Transduct Target Ther. 2022 Feb 28;7(1):54./SSRN. 2021 Jun./STAR Protoc. 2022 Apr 13;3(2):101296./STAR Protoc. 2022 Nov 2;3(4):101808./Stem Cell Rev Rep. 2023 Jan 11./Stem Cells Int. 2020 Aug 29;2020:8860185. /Thorac Cancer. 2024 May 8./Transl Oncol. 2024 Apr 24:45:101958./Transl Oncol. 2024 Jul 3:47:101950./Vet Microbiol. 2023 Jun 28;284:109823./Virus Res. 2023 Apr 15;328:199086./Acta Pharmacol Sin. 2021 Jan;42(1):108-114./Adv Funct Mater. 2019, 1808556./Biochem Pharmacol. 2017 Mar 15;128:12-25./bioRxiv. 2023 Jun 17./Cancer Cell Int. 2019 Jul 24;19:192. /Cancer Immunol Res. 2023 May 2;CIR-22-0814./Cell Signal. 2019 Mar 5;58:119-130. /Evid Based Complement Alternat Med. 2019 Mar 24;2019:1635837./Hepatology. 2021 Apr;73(4):1327-1345./Int J Oncol. 2020 Jul;57(1):161-170./J Cell Mol Med. 2019 Feb;23(2):954-966./J Exp Clin Cancer Res. 2016 Nov 7;35(1):173. /Onco Targets Ther. 2019 Jan 25;12:835-848. /PLoS One. 2017 Oct 10;12(10):e0185565./R Soc Open Sci. 2018 Aug 29;5(8):172376./Theranostics. 2020 May 16;10(14):6483-6499. /Theranostics. 2021 Mar 5;11(10):5045-5060./Toxicol Appl Pharmacol. 2019 Sep 1;378:114625. /Transl Res. 2023 Apr 28;S1931-5244(23)00072-5.
References: [1]Nathans D, et al. Puromycin inhibition of protein synthesis: incorporation of puromycin intopeptide chains. Proc Natl Acad Sci U S A. 1964 Apr;51:585-92./[2]Miyamoto-Sato E, et al. Specific bonding of puromycin to full-length protein at the C-terminus. Nucleic Acids Res. 2000 Mar 1;28(5):1176-82./[3]Schmidt EK, et al. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009 Apr;6(4):275-7.
CAS Number: 58-58-2
Molecular Weight: 544.43
Compound Purity: 99.89
Research Area: Infection
Solubility: DMSO : 50 mg/mL (ultrasonic)/Ethanol : 5 mg/mL (ultrasonic;warming;heat to 60°C)/H2O : 50 mg/mL (ultrasonic;warming)/Methanol : 250 mg/mL (ultrasonic)
Target: Antibiotic;Bacterial;Parasite
English
Deutsch
